

Chiesi and Aptar partner to bring to market Disease Management Platform for patients with asthma and COPD

- The new digital health solution aims to offer patients and healthcare professionals a comprehensive set of services and solutions targeted at improving outcomes for chronic respiratory diseases.

Manchester, UK, 19th October 2022 – Chiesi, the international research-focused biopharmaceutical and healthcare group, and Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic partnership to bring to market Aptar's recently announced Disease Management Platform for asthma and chronic obstructive pulmonary disease (COPD).

This platform is designed to empower patients to better understand and take control of their disease and provide healthcare professionals with data-driven insights to better manage their patients and build evidence for emerging reimbursement arrangements in the field of digital health for asthma and COPD. The platform offers a comprehensive set of services and solutions aimed at bringing together both the pharmacological and behavioural aspects of managing respiratory diseases; these include adherence monitoring, lung function assessment, reporting symptoms and identifying disease triggers and communication with care teams and health coaches. The partnership initially focuses on Europe, with potential future expansions to other geographies.

Chronic respiratory conditions such as asthma and COPD represent an enormous burden on healthcare systems in the UK. It is estimated that 5.4 million in the UK (one in 12 adults and one in 11 children) have asthma, while 1.2 million have diagnosed COPD.^{1,2} A report by the British Lung Foundation found that that asthma and COPD are among the conditions with the greatest economic burden on health services in the UK, costing the NHS £3 billion and £1.9 billion a year respectively.³

Part of the solution to this challenge is to provide healthcare professionals, patients, and caregivers with the appropriate tools to promote disease monitoring, adherence to treatment, access to non-pharmacological behavioural interventions, and adequate and sustainable care. Crucially, a European report found that patients with asthma and COPD have indicated a willingness to embrace digital tools that empower them and can help improve outcomes.⁴

*"This collaboration reflects our commitment to providing best-in-class level of care for people living with COPD and asthma, going beyond treatments alone and focusing on the patient experience," commented **Alessandro Chiesi**, Chief Commercial Officer of the Chiesi Group. "We are looking forward to leveraging Aptar Digital Health's deep expertise in disease management with the goal to improve the quality of life of patients afflicted with respiratory diseases and procure tools that contribute to the sustainability of healthcare services for chronic conditions."*

*"Aptar Digital Health, with its technology and pharma expertise, is uniquely positioned to offer such a complete solution - from software to connected devices to patient monitoring and data analysis," said **Gael Touya**, President of Aptar Pharma. "We are delighted to partner with Chiesi and excited to be able to actively contribute to expanding patient access to holistic, end-to-end services that will durably enhance their respiratory disease management."*

###

About Chiesi Group

Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment. By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. Since 2019 Chiesi is certified B Corp, meaning that its sustainability efforts are measured and assessed by the most ambitious global standards. The company aims at becoming net-zero by 2035. With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 30 countries, and counts more than 6,000 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For more information, please visit www.chiesi.uk.com.

About Aptar Digital Health

Aptar Pharma's Digital Health division is part of AptarGroup, Inc., a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions and services. Aptar Digital Health creates end-to-end solutions to enhance patient experiences every day, leveraging a holistic ecosystem of digital interventions. Amplified by an industry-leading portfolio of products and solutions, Aptar Digital Health's offerings combine mobile and web apps, connected drug delivery systems, onboarding, training and advanced data analytics services to actively empower patients and create a positive treatment journey. Aptar is headquartered in Crystal Lake, Illinois and has 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Media contact

Donna Caslin
Senior PR and Communications Manager
Phone: (+44) 161 488 5555
Email: d.caslin@chiesi.com

References

¹ Asthma + Lung UK. What is asthma? Available at: <https://www.asthma.org.uk/advice/understanding-asthma/what-is-asthma>. Accessed October 2022.

² British Lung Foundation. Chronic obstructive pulmonary disease (COPD) statistics. Available at: <https://statistics.blf.org.uk/copd>. Accessed October 2022.

³ British Lung Foundation. Estimating the economic burden of respiratory illness in the UK. Available at: <https://www.blf.org.uk/policy/economic-burden>. Accessed October 2022.

⁴ European Federation of Allergy and Airways Diseases Patients' Associations. The asthma and COPD patients' digital journey in Europe. Available at: https://efanet.org/images/2022/EFA_DIG_IT_Full_Report.pdf. Accessed October 2022.